Caribou Biosciences will webcast new clinical trial data for CAR-T therapies vispa-cel and CB-011 on November 3, 2025.
Quiver AI Summary
Caribou Biosciences, Inc. announced a webcast on November 3, 2025, to present new data from its ANTLER phase 1 clinical trial of vispacabtagene regedleucel (vispa-cel), an allogeneic anti-CD19 CAR-T cell therapy for patients with relapsed or refractory B cell non-Hodgkin lymphoma, and data from the CaMMouflage Phase 1 trial of CB-011, an allogeneic anti-BCMA CAR-T cell therapy for patients with relapsed or refractory multiple myeloma. The company will also discuss the anticipated design of the pivotal phase 3 trial for vispa-cel and the next steps for CB-011's development. Both therapies have received FDA designations that facilitate their clinical development. Caribou aims to utilize its CRISPR genome-editing technology to create effective off-the-shelf CAR-T cell treatments that improve patient access to care.
Potential Positives
- Caribou Biosciences is set to report new clinical data from the ANTLER phase 1 trial for vispacabtagene regedleucel (vispa-cel), potentially showcasing advancements in treating relapsed or refractory B cell non-Hodgkin lymphoma.
- The company will also present first clinical data from the CaMMouflage Phase 1 trial for CB-011, an innovative anti-BCMA CAR-T therapy, indicating progress in addressing relapsed or refractory multiple myeloma.
- Both vispa-cel and CB-011 have received Fast Track and Orphan Drug designations from the FDA, highlighting their potential significance in treating hematologic malignancies and expediting their development process.
- The ability to webcast and archive these presentations allows for wider accessibility and transparency regarding their research and clinical developments, potentially attracting investor interest.
Potential Negatives
- The press release does not provide any significant new data or findings about the ongoing clinical trials, which may lead to skepticism about the company’s progress and transparency.
- The webcast scheduled to report ANTLER and CaMMouflage trial data may come under scrutiny if the reported results are underwhelming or do not meet investor expectations.
FAQ
What is the date and time of Caribou's upcoming webcast?
Caribou's webcast will be on November 3, 2025, at 8:00 AM ET.
What clinical trials will be discussed in the webcast?
The webcast will cover the ANTLER and CaMMouflage Phase 1 clinical trials.
What is vispacabtagene regedleucel (vispa-cel)?
Vispa-cel is an allogeneic anti-CD19 CAR-T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma.
What is CB-011 in the context of Caribou's research?
CB-011 is an allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma.
How can I access the webcast after the event?
The archived webcast will be available on Caribou's website for 30 days after the event.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CRBU Hedge Fund Activity
We have seen 54 institutional investors add shares of $CRBU stock to their portfolio, and 84 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 4,462,962 shares (-70.3%) from their portfolio in Q2 2025, for an estimated $5,623,332
- STATE STREET CORP removed 1,283,018 shares (-78.2%) from their portfolio in Q2 2025, for an estimated $1,616,602
- PFM HEALTH SCIENCES, LP removed 1,147,604 shares (-45.8%) from their portfolio in Q2 2025, for an estimated $1,445,981
- GEODE CAPITAL MANAGEMENT, LLC removed 1,073,000 shares (-52.2%) from their portfolio in Q2 2025, for an estimated $1,351,980
- JPMORGAN CHASE & CO removed 803,844 shares (-99.9%) from their portfolio in Q2 2025, for an estimated $1,012,843
- FMR LLC removed 730,657 shares (-50.0%) from their portfolio in Q2 2025, for an estimated $920,627
- MILLENNIUM MANAGEMENT LLC added 729,538 shares (+88.9%) to their portfolio in Q2 2025, for an estimated $919,217
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BERKELEY, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hold a webcast beginning at 8:00 am ET on Monday, November 3, 2025, to report new data from the ANTLER phase 1 clinical trial evaluating vispacabtagene regedleucel (vispa-cel; formerly CB-010), an allogeneic anti-CD19 CAR-T cell therapy, in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) and report the first clinical data from the CaMMouflage Phase 1 clinical trial evaluating CB-011, an allogeneic anti-BCMA CAR-T cell therapy, in patients with r/r multiple myeloma. The Company will also report its anticipated pivotal phase 3 trial design for vispa-cel and next steps for the continued clinical development of CB-011.
A live webcast of the presentation will be accessible via Caribou’s website on the Events page. The archived webcast will be available on the Caribou website for 30 days after the event.
About vispacabtagene regedleucel
Vispacabtagene regedleucel (vispa-cel; formerly known as CB-010) is an allogeneic anti-CD19 CAR-T cell therapy being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). To Caribou’s knowledge, vispa-cel is the first allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to enhance CAR-T cell activity by limiting premature CAR-T cell exhaustion. The FDA granted vispa-cel Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track designations for B-NHL. Additional information on the ANTLER trial (
NCT04637763
) can be found at
clinicaltrials.gov
.
About CB-011
CB-011 is an allogeneic anti-BCMA CAR-T cell therapy being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage Phase 1 trial. To Caribou’s knowledge, CB-011 is the first allogeneic CAR-T cell therapy in the clinic that is engineered to enable activity through an immune cloaking strategy with a B2M knockout and insertion of a B2M–HLA-E fusion protein to blunt immune-mediated rejection. CB-011 has been granted Fast Track and Orphan Drug designations by the FDA. Additional information on the CaMMouflage trial (
NCT05722418
) can be found at
clinicaltrials.gov
.
About Caribou Biosciences, Inc.
Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow the Company @CaribouBio and visit
www.cariboubio.com
.
Caribou Biosciences, Inc. contact:
Peggy Vorwald, PhD
[email protected]
[email protected]
